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Background: Severity of viral respiratory illnesses can be increased with 
bacterial coinfection and can vary by sex, but influence of coinfection and 
sex on human endemic coronavirus (CoV) species, which generally cause 
mild to moderate respiratory illness, is unknown. We evaluated CoV and 
pneumococcal co-detection by sex in childhood pneumonia.
Methods: In the 2011–2014 Pneumonia Etiology Research for Child Health 
study, nasopharyngeal and oropharyngeal (NP/OP) swabs and other samples 
were collected from 3981 children <5 years hospitalized with severe or very 
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pneumococcus (HDSpn) by real-time polymerase chain reaction was 
assessed by sex using logistic regression adjusted for age and site.
Results: There were 43 (1.1%) CoV+/HDSpn+, 247 CoV+/HDSpn−, 
449 CoV−/HDSpn+ and 3149 CoV−/HDSpn− cases with no significant 
difference in co-detection frequency by sex (range 51.2%–64.0% male, 
P = 0.06). More CoV+/HDSpn+ pneumonia was very severe compared with 
other groups for both males (13/22, 59.1% versus range 29.1%–34.7%, 
P = 0.04) and females (10/21, 47.6% versus 32.5%–43.5%, P = 0.009), but 
only male CoV+/HDSpn+ required supplemental oxygen more frequently 
(45.0% versus 20.6%–28.6%, P < 0.001) and had higher mortality (35.0% 
versus 5.3%–7.1%, P = 0.004) than other groups. For females with CoV+/
HDSpn+, supplemental oxygen was 25.0% versus 24.8%–33.3% (P = 0.58) 
and mortality was 10.0% versus 9.2%–12.9% (P = 0.69).
Conclusions: Co-detection of endemic CoV and HDSpn was rare in chil-
dren hospitalized with pneumonia, but associated with higher severity and 
mortality in males. Findings may warrant investigation of differences in 
severity by sex with co-detection of HDSpn and SARS-CoV-2.
Key Words: coronavirus, pneumococcus, coinfection, pneumonia, 
COVID-19
(Pediatr Infect Dis J 2021;XX:00–00)
Bacterial coinfection increased morbidity and mortality in both the 1918 and 2009 influenza A pandemics.1,2 By some esti-
mates, >95% of the deaths during the 1918 influenza pandemic 
involved complication with bacterial pneumonia, most commonly 
with Streptococcus pneumoniae.1,3 In a large-scale clinical study 
across the United States during the 2009 H1N1 pandemic, 28% 
of H1N1 2009 virus-positive samples had at least 1 other patho-
gen detected.4 In nonpandemic contexts, pneumonia etiology stud-
ies have attributed around 10%–30% of hospitalized pneumonia 
to multiple pathogens, particularly to coinfection with respiratory 
viruses and pneumococcus.5–8
In late 2019, a novel enveloped RNA coronavirus (CoV) 
designated SARS-CoV-2 emerged and proliferated globally, caus-
ing the associated illness named the 2019 coronavirus disease 
(COVID-19).9–12 While most COVID-19 cases were adults, severe 
disease and mortality have been reported in children.13,14 Initial 
studies suggest that pneumococcal coinfection with COVID-19 is 
relatively rare15,16; however, diagnosing coinfection remains chal-
lenging because similar clinical presentation and poor sensitivity 
of detecting pneumococcal pneumonia. In adults, pneumococcal 
pneumonia diagnosis relies on sputum and bronchoscopy, which 
have been restricted during the pandemic,16–18 and blood cultures 
which only detect approximately 25% of cases.19 Prior studies 
have suggested that high-density detection of pneumococcus in the 
nasopharynx or oropharynx may be an informative proxy for pneu-
mococcal pneumonia and help differentiate disease from coloniza-
tion.20,21 Pneumococcal carriage itself may also contribute to sever-
ity, as high-density carriage of S. pneumoniae has been associated 
with immunologic priming, upper respiratory tract microbiome 
dysbiosis and increased susceptibility to viral coinfection.22,23
Differences in severity of disease by sex have been observed 
for influenza, SARS-CoV-2 and pneumococcus. Severity of influ-
enza disease and COVID-19 is generally greater in males, includ-
ing in male children.24,25 Incidence and severity of invasive pneu-
mococcal disease (IPD) is also higher in males.26–29 The relative 
contribution of behavioral and biologic causes for sex differences 
is unknown.25,30–32
Other endemic CoV species have received less attention 
than SARS-CoV-2 because most infections are asymptomatic or 
mild, although severe disease and mortality have been reported 
in both children and adults.13,14 Endemic CoVs commonly found 
in human circulation include CoV-NL63, CoV-229E, CoV-HKU1 
and CoV-OC43, of which CoV-HKU1 and CoV-OC43 are more 
closely related to SARS-CoV-2.12 There is in vitro evidence for co-
pathogenesis of endemic CoV with pneumococcus,33 and in vivo 
data from a pneumococcal conjugate vaccine trial suggesting that 
pneumococcus may play a role in severe endemic CoV infections.34 
However, few studies have examined evidence for co-pathogenesis 
at the population level.7 Endemic CoVs have been commonly found 
in children, both in healthy children and those hospitalized with 
pneumonia, but are not estimated to be a common cause of pneu-
monia.35
The Pneumonia Etiology Research for Child Health 
(PERCH) study evaluated the causes of hospitalized severe or 
very severe pneumonia in children in 7 developing countries, and 
included community controls to evaluate the background preva-
lence of infection in children without pneumonia.35 To explore 
severity of pneumonia associated with S. pneumoniae and endemic 
CoV coinfection and evaluate differences by sex, we evaluated the 
clinical and epidemiologic characteristics of NP/OP co-detection 
in the PERCH study.
MATERIALS AND METHODS
PERCH enrollment occurred between August 2011 and 
November 2014 for 24 months at each of 9 study sites in 7 coun-
tries: Dhaka and Matlab, Bangladesh; Basse, The Gambia; Kilifi, 
Kenya; Bamako, Mali; Soweto, South Africa; Nakhon Phanom and 
Sa Kaeo, Thailand; and Lusaka, Zambia. Identification and selec-
tion of cases and controls have been described previously.36 Cases 
were children 28 days–59 months of age hospitalized with severe 
or very severe pneumonia (pre-2013 WHO definition). Severe 
pneumonia was defined as having cough or difficulty breathing and 
lower chest wall indrawing; very severe pneumonia was defined as 
cough or difficulty breathing and at least one of the following dan-
ger signs: central cyanosis, difficulty breast-feeding/drinking, vom-
iting everything, convulsions, lethargy, unconsciousness or head 
nodding. Exclusion criteria for cases were hospitalization within 
the previous 14 days, having been discharged as a PERCH case 
within the past 30 days, not residing in the study catchment area, or 
resolution of lower chest wall indrawing following bronchodilator 
therapy for those with wheeze.37 Controls were children randomly 
selected from the same communities as cases without symptoms 
of severe or very severe pneumonia who were frequency-matched 
by age-group and month of enrollment to the cases. Known HIV-
positive participants were excluded from this analysis; children 
with unknown HIV-status from sites with low HIV prevalence were 
included. The study protocol was approved by the Institutional 
Review Boards or Ethical Review Committees at all 7 institutions 
and at The Johns Hopkins School of Public Health.
Sample collection methods have been described previ-
ously.38,39 In brief, a flocked nasopharyngeal (NP) swab (flexible 
minitip, Copan) and a rayon oropharyngeal (OP) swab specimen 
were collected from each case and control at enrollment and 
placed pooled into the same 3 mL vial of universal transport media 
(Copan). The NP/OP specimen was tested for pneumococcus (lytA 
gene target) and coronaviruses NL63, 229E, OC43 and HKU1 
as part of a multiplex real-time polymerase chain reaction (PCR) 
assay (FTD Respiratory Pathogens 33, Fast-track Diagnostics, 
Sliema, Malta). Colonization density was quantified in copies per 
mL by applying standard curves from standards of known quan-
tities. Pathogen-specific high-density thresholds were determined 
for common bacterial colonizers, including pneumococcus. The 
threshold of upper respiratory tract carriage density that best dis-
tinguished known pneumococcal cases from controls was ≥6.9 log 
copies/mL.20,40,41
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Clinical characterization of the illness in cases was assessed 
at admission. Digital chest radiograph images were assessed by 
members of a panel of 14 radiologists and pediatricians who were 
trained in the standardized interpretation of pediatric chest radio-
graphs.42
Coinfection status for primary analyses were defined using 
NP/OP detection as follows: coronavirus with high-density S. 
pneumoniae (CoV+/HDSpn+), coronavirus without high-density 
S. pneumoniae (CoV+/HDSpn−), HDSpn without coronavirus 
(CoV−/HDSpn+) and neither HDSpn nor coronavirus (CoV−/
HDSpn−). A secondary analysis evaluated NP/OP CoV co-detec-
tion with 3 categories of S. pneumoniae density: (1) no S. pneu-
moniae; (2) low-density pneumococcus (<6.9 log
10
 copies/mL); 
and (3) high-density pneumococcus. Prevalence of co-detection 
in cases was compared with controls. We evaluated associations 
between density of CoV and pneumococcal density category, sex 
and mortality. To assess whether findings were unique to CoV and 
S. pneumoniae co-detections, supplemental analyses evaluated co-
detection of CoV with Haemophilus influenzae and Staphylococ-
cus aureus, and co-detection of S. pneumoniae with influenza A, 
B or C, human metapneumovirus, parainfluenzavirus 1 or 3 (Para 
1/3) and respiratory syncytial virus A and B (RSV A/B). A sensi-
tivity analysis was conducted to expand the definition of CoV+ to 
include CoV detected in induced sputum by PCR and the definition 
of HDSpn+ to include IPD cases that fell below the threshold, that 
is, had S. pneumoniae recovered from blood by culture or from lung 
aspirate or pleural fluid by culture or PCR. A second sensitivity 
analysis lowered the pneumococcal density threshold to 6.6 log
10
 
copies/mL, which better aligned with detection of pneumococcal 
pneumonia from children with prior antibiotic use.20
Statistical Analysis
Demographic, clinical and laboratory characteristics were 
compared by co-detection category using logistic regression 
adjusted for age and site for categorical variables or the Wilcoxon 
signed-rank test for continuous variables, with and without stratify-
ing by sex. Wilson score intervals were used to generate binomial 
proportional confidence intervals (CIs). Certain models were only 
adjusted for age and subregion (Asia, Western Africa, Southern 
Africa and Eastern Africa) due to sample size limitations. Interac-
tion terms for sex were included in regression models to test for 
differences in association between co-detection and covariates by 
sex. Other pathogen combinations were selected based on prior 
evidence in the literature and through Random Forest models to 
evaluate all potential pathogens as predictors of CoV detection. 
Statistical analyses were conducted in SAS, version 9.4, and R, 
version 3.3.1.
RESULTS
Of 3888 HIV-negative cases enrolled between 2011 and 
2014 with WHO-defined severe or very severe pneumonia with 
available NP/OP results, 7.5% (n = 290) had endemic coronavi-
rus detected by NP/OP PCR (2.2% NL63, 1.1% 229E, 2.8% OC43 
and 1.6% HKU1) and 492 (12.6%) had HDSpn detected. CoV+/
HDSpn+ was observed in 43 (1.1%) cases, CoV+/HDSpn− in 247 
(6.4%), CoV−/HDSpn+ in 449 (11.5%) and 3149 (81.0%) had nei-
ther. S. pneumoniae was detected by blood culture more frequently 
in HDSpn+ cases and most frequently in those also CoV+: CoV+/
HDSpn+ 7.1%, CoV−/HDSpn+ 4.3%, CoV+/HDSpn− 1.2% and 
CoV−/HDSpn− 0.3% (Table S12, Supplemental Digital Con-
tent 1, http://links.lww.com/INF/E363). Controls (n = 4977) had 
higher CoV prevalence than cases (10.0% versus 7.5%), but CoV+/
HDSpn+ prevalence was similar between cases and controls (1.1% 
versus 0.9%) (Table 1).
Co-detection of Endemic CoV and HDSpn
Co-detection was not associated with age, sex or pneumococ-
cal conjugate vaccination status, but CoV+/HDSpn+ cases were dis-
proportionately from Mali (Table 2) (Supplemental Digital Content 1 
and 2, http://links.lww.com/INF/E363). Cases with high pneumococ-
cal density, with or without CoV, were half as likely to have received 
antibiotics before NP/OP swab collection compared with cases with-
out high-density pneumococcus (24.4% versus 47.4%, P < 0.001).
The association between the case co-detection group and 
clinical signs and symptoms at admission differed by gender 
(Table 3). For males only, CoV+/HDSpn+ cases were significantly 
more likely than the other co-detection groups to have WHO-
defined very severe pneumonia (59.1% versus range 29.1%–34.7%, 
P = 0.04), require supplemental oxygen (45.0% versus 20.6%–
28.6%, P < 0.001), have an mid-upper arm circumference-for-age 
Z-score < −3 SD (21.4% versus 2.6%–14.6%, P = 0.005). Among 
females only, leukocytosis was highest in CoV+/HDSpn+ cases 
(P = 0.01; interaction by sex P = 0.06) and an abnormal chest radi-
ograph was least common among CoV+/HDSpn+ cases (28.6%) 
compared with the other co-detection groups (53.4%–65.8%, 
P = 0.03); for males, the abnormal chest radiograph was more 
common in HDSpn+ cases regardless of CoV status (64.7% and 
58.1% for CoV+ and CoV−, respectively) compared with HDSpn− 
cases (43.8% and 49.4%, respectively; P = 0.03; interaction by sex 
P = 0.04). Other sex differences included less tachypnea among 
CoV+ in males (P = 0.009) but no difference among co-detection 
groups in females (interaction by sex P = 0.04). Fever at admis-
sion was common in all groups, but in males was more common 
among HDSpn+ cases (92.7%) compared with HDSpn− cases 
(79.8%, P = 0.03), whereas fever in females was most common in 
CoV−/HDSpn+ cases (90.8%) compared with other groups (range 
80.9%–81.0%, P = 0.02; interaction by sex P = 0.99). Median 
C-reactive protein was highest among CoV+/HDSpn+ cases in 
males (44.3 versus 14.6–22.6 mg/L, P < 0.001) and was highest in 
HDSpn+ cases regardless of CoV status for females (Supplemental 
Digital Content 3 and 4, http://links.lww.com/INF/E363).
The overall case fatality ratio (CFR) among all PERCH 
HIV-negative cases was higher in females (8.9%) than males (7.4%, 
P < 0.001) (Supplemental Digital Content 5, http://links.lww.com/
INF/E363). The CFR was highest in CoV+/HDSpn+ cases (22.5%, 
n = 9/40) compared with the other coinfection groups (7.2%–9.7%, 
P = 0.053) (Supplemental Digital Content 6, http://links.lww.com/
INF/E363). When stratified by sex, this association was seen only 
among males (interaction by sex P = 0.02) among whom CoV+/
HDSpn+ CFR was 35.0% (n = 7/20, 95% CI 18.1%–56.7%) com-
pared with 5.3%–7.1% in the other groups (P = 0.004). In females, 
the CFR among CoV+/HDSpn+ was 10.0% (n = 2/20) and 9.2%–
12.9% in other groups (P = 0.69, Fig. 1). After adjusting for age, 
site and malnutrition, the odds ratio of mortality in CoV+/HDSpn+ 
male cases compared with CoV+/HDSpn−, CoV−/HDSpn+ and 
CoV−/HDSpn− male cases was 11.6 (95% CI 3.1–44.4), 5.9 
(1.7–20.3) and 8.6 (3.1–24.2), respectively (Supplemental Digital 
Content 7, http://links.lww.com/INF/E363). Among male children 
with CoV who died, 46.7% (n = 7/15; 95% CI 21.4%–71.9%) were 
HDSpn+ in NP/OP. Males without pneumococcus detected on NP/
OP swabs had significantly higher CFR than males with low-den-
sity (<6.9 log
10
 copies/mL) pneumococcal upper respiratory tract 
carriage (CoV+: 10.2% versus 3.0%, P = 0.05; CoV−: 7.4% versus 
4.9%, P = 0.02) Supplemental Digital Content 8, http://links.lww.
com/INF/E363). CFR was similar across pneumococcal density 
categories for female children (range 8.2%–13.3%).
The CoV NP/OP viral load was similar among males and 
females (median 5.2 and 5.3 log
10
 copies/mL, respectively) and did 
not differ significantly by pneumococcal load (range 4.9–5.8 log
10
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copies/mL between noncarriers, LDSpn and HDSpn, P = 0.36) 
(Supplemental Digital Content 9 and 10, http://links.lww.com/INF/
E363). Viral load was slightly higher among children who died 
compared with those that survived (median 5.7 versus 5.2 log
10
 cop-
ies/mL; P = 0.09), and was significantly higher when restricted to 
HDSpn+ cases (median 7.2 versus 5.6 log
10
 copies/mL, P = 0.03). 
Pneumococcal and CoV NP/OP densities and other organisms 
detected from sterile site and NP/OP swabs are described for fatal 
CoV+ cases with and without HDSpn co-detection in Supplemental 
Digital Content 11 and 12, http://links.lww.com/INF/E363. Among 
CoV+/HDSpn+ children who died, a median of 2 additional organ-
isms were detected by NP/OP PCR (Supplemental Digital Con-
tent 13, http://links.lww.com/INF/E363), and 2 nonpneumococcal 
organisms were detected from sterile sites.
Two sensitivity analyses were conducted that evaluated other 
definitions of CoV and HDSpn: (1) included CoV detected in induced 
sputum specimens, which added 97 CoV+ cases, and included micro-
biologically confirmed pneumococcal pneumonia cases to HDSpn+, 
TABLE 2. Characteristics of Children Hospitalized with Severe or Very Severe Pneumonia by NP/OP  
Co-detection Status of Endemic Coronavirus (CoV-NL63, CoV-229E, CoV-OC43 or CoV-HKU1) and HDSpn*
Characteristic
No. (% with Available Information)
P†A. CoV+/HDSpn+ B. CoV+/HDSpn− C. CoV−/HDSpn+ D. CoV− and HDSpn−
Total 43 (100) 247 (100) 449 (100) 3149 (100)  
Age <1 yr 27 (62.8) 174 (70.4) 284 (63.3) 1980 (62.9) 0.129
Male sex 22 (51.2) 158 (64.0) 242 (53.9) 1826 (58.0) 0.058
Site     <0.001
 Bangladesh 5 (11.6) 33 (13.4) 63 (14.0) 424 (13.5)  
 Thailand 0 (0) 10 (4.0) 3 (0.7) 208 (6.6)  
 Mali 18 (41.9) 53 (21.5) 148 (33.0) 431 (13.7)  
 The Gambia 9 (20.9) 48 (19.4) 95 (21.2) 457 (14.5)  
 South Africa 6 (14.0) 54 (21.9) 81 (18.0) 654 (20.8)  
 Zambia 3 (7.0) 25 (10.1) 31 (6.9) 401 (12.7)  
 Kenya 2 (4.7) 24 (9.7) 28 (6.2) 574 (18.2)  
PCV vaccination status‡      
No. doses     0.226
 0 14 (35.0) 91 (38.2) 165 (37.8) 1359 (44.5)  
 1–2 10 (25.0) 80 (33.6) 128 (29.4) 787 (25.8)  
 ≥3 16 (40.0) 67 (28.2) 143 (32.8) 910 (29.8)  
Fully vaccinated for age 22 (55.0) 129 (54.2) 235 (53.9) 1456 (47.6) 0.307
Antibiotics received before NP/OP collection§ 7 (16.3) 113 (45.7) 113 (25.2) 1498 (47.6) <0.001
*≥6.9 log copies/mL.
†P values for age in months obtained from the Wilcoxon test. The overall P value obtained from multinomial logistic regression adjusted for age and site (where appli-
cable).
‡During the study, PCV was in routine use in Kenya (introduced February, 2011), The Gambia (August, 2009), Mali (March, 2011) and South Africa (April, 2009); PCV 
was introduced in Zambia in July, 2013 (Lusaka), 3 months before the end of study enrollment. For children younger than 1 year, full vaccination was defined as having 
received at least 1 dose and being up to date for age on the basis of the child’s age at enrollment, doses received and country schedule (allowing a 4-week window for each 
dose); for children 1 year or older in all sites except Kenya, full vaccination was defined as having received three or more doses; for children older than 1 year in Kenya (which 
introduced PCV with catch-up campaign), full vaccination was defined as having received three or more doses, two doses if given at least 8 weeks apart and the child was 
older than 1 year of age at first dose, and one dose if the child was older than 2 years at any dose or at introduction.
§Defined as serum bioassay positive, antibiotics administered at the referral facility or antibiotic administration before the collection of NP/OP PCR specimens at the 
study facility.
CoV indicates coronavirus; HDSpn, high-density Streptococcus pneumoniae; PERCH, Pneumonia Etiology Research for Child Health; PCV, pneumococcal conjugate 
vaccine; NP/OP, nasopharyngeal/oropharyngeal.
TABLE 1. Distribution of Human Endemic Coronavirus (CoV-NL63, CoV-229E, CoV-OC43 
or CoV-HKU1) and HDSpn Co-detection Status in NP/OP by PERCH Case-control Status
Characteristic Case (n = 3888) Control (n = 4977) aOR*; Case vs. Control (Ref) P
Coronavirus positive, n 290 501   
 Prevalence, % (95% CI) 7.5 (6.7–8.3) 10.1 (9.3–10.9) 0.67 (0.58–0.78) <0.001
High-density Spn, n 492 379   
 Prevalence, % (95% CI) 12.7 (11.7–13.7) 7.6 (6.9–8.4) 1.62 (1.40–1.87) <0.001
Co-detection category     
 CoV+/HDSpn+, n 43 47   
  Prevalence, % (95% CI) 1.1 (0.8–1.5) 0.9 (0.7–1.3) 1.09 (0.71–1.66) 0.698
 CoV+/HDSpn−, n 247 454   
  Prevalence, % (95% CI) 6.4 (5.6–7.2) 9.1 (8.4–10.0) 0.63 (0.54–0.75) <0.001
 CoV-/HDSpn+, n 449 332   
  Prevalence, % (95% CI) 11.5 (10.6–12.6) 6.7 (6.0–7.4) 1.69 (1.45–1.97) <0.001
 CoV-/HDSpn−, n 3149 4143   
  Prevalence, % (95% CI) 81.0 (79.7–82.2) 83.3 (82.3–84.3) 0.96 (0.86–1.07) 0.433
*Odds ratio for case status compared with control, adjusted for age in months and site.
CoV indicates coronavirus; HDSpn, high-density Streptococcus pneumoniae; PERCH, Pneumonia Etiology Research for Child Health 
study; NP/OP, nasopharyngeal/oropharyngeal.
The Pediatric Infectious Disease Journal • Volume XX, Number XX, XXX XXX 
© 2021 The Author(s). Published by Wolters Kluwer Health, Inc. www.pidj.com | 5
Coronavirus and Pneumococcal Co-detection
TABLE 3. Clinical Characteristics at Admission of Children Hospitalized with Severe or Very Severe Pneumonia by NP/
OP Co-detection Status of Endemic Coronavirus (CoV-NL63, CoV-229E, CoV-OC43 or CoV-HKU1) and HDSpn*, by Sex
Characteristics
No. (% with Available Information)   
A. B. C. D.













 Male 22 (51.2) 158 (64.0) 242 (53.9) 1826 (58.0)   
 Female 21 (48.8) 89 (36.0) 207 (46.1) 1323 (42.0)   
Very severe pneumonia  
(2005 WHO definition)
23 81 174 969 <0.001 0.335
(53.5) (32.8) (38.8) (30.8)   
 Male 13 46 84 539 0.039  
(59.1) (29.1) (34.7) (29.5)   
 Female 10 35 90 430 0.009  
(47.6) (39.3) (43.5) (32.5)   
Hypoxemia at admission 17 90 183 1098 0.061 0.873
(39.5) (36.6) (40.9) (35.0)   
 Male 8 49 91 592 0.182  
(36.4) (31.0) (37.6) (32.5)   
 Female 9 41 92 506 0.265  
(42.9) (46.6) (44.7) (38.3)   
WHO defined very severe or  
hypoxemia
30 130 254 1601 0.002 0.697
(69.8) (52.9) (56.6) (50.9)   
 Male 16 74 125 885 0.094  
(72.7) (46.8) (51.7) (48.5)   
 Female 14 56 129 716 0.015  
(66.7) (63.6) (62.3) (54.2)   
Supplemental oxygen (ever)‡ 13/36 48/192 99/367 687/2475 0.001 0.240
(36.11) (25.0) (27.0) (27.8)   
 Male 9/20 26/126 59/206 373/1460 <0.001  
(45.0) (20.6) (28.6) (25.5)   
 Female 4/16 22/66 40/161 314/1015 0.584  
(25.0) (33.3) (24.8) (30.9)   
Tachypnea 38 199 398 2546 0.044 0.036
(88.4) (81.2) (88.6) (81.5)   
 Male 17 122 220 1479 0.009  
(77.3) (77.2) (90.9) (81.5)   
 Female 21 77 178 1067 0.423  
(100.0) (88.5) (86.0) (81.5)   
Fever 37 193 400 2533 0.001 0.986
(86.1) (78.1) (89.1) (80.4)   
 Male 20 121 212 1462 0.025  
(90.9) (76.6) (87.6) (80.1)   
 Female 17 72 188 1071 0.017  
(81.0) (80.9) (90.8) (81.0)   
Observed cough 22 168 302 2215 0.175 0.597
(51.2) (68.0) (67.4) (70.6)   
 Male 10 110 167 1310 0.204  
(45.5) (69.6) (69.0) (71.9)   
 Female 12 58 135 905 0.720  
(57.1) (65.2) (65.5) (68.7)   
Vomiting 12 49 104 643 0.382 0.109
(28.6) (19.8) (23.2) (20.4)   
 Male 9 28 52 358 0.133  
 (40.9) (17.7) (21.5) (19.6)   
 Female 3 21 52 285 0.726  
 (15.0) (23.6) (25.1) (21.5)   
Diarrhea 9 38 86 439 0.062 0.380
(20.9) (15.4) (19.2) (13.9)   
 Male 5 27 53 248 0.004  
 (22.7) (17.1) (22.0) (13.6)   
 Female 4 11 33 191 0.816  
 (19.1) (12.4) (16.0) (14.4)   
Abnormal chest radiograph‡ 15/31 110/213 220/377 1381/2706 0.077 0.043
(48.4) (51.6) (58.4) (51.0)   
 Male 11/17 60/137 119/205 783/1585 0.030  
(64.7) (43.8) (58.1) 49.4)   
 Female 4/14 50/76 101/172 598/1121 0.030  
(28.6) (65.8) (58.7) (53.4)   
(Continued)
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which added three cases; (2) decreased the pneumococcal density 
threshold to 6.6 log
10
 copies/mL, which added 215 HDSpn+ cases 
(Supplemental Digital Content 14, http://links.lww.com/INF/E363). 
All findings were consistent with the primary analysis.
Co-detection of Other Potential Pathogens
High-density H. influenzae colonization of the upper airway 
was the strongest bacterial predictor of CoV detection by random 
forest analysis (data not shown), but co-detection of CoV and 
Weight-for-height Z-score < −3 SDs 5 25 73 338 0.118 0.077
(11.9) (10.6) (16.6) (11.1)   
 Male 4 19 43 184 0.052  
(19.1) (12.3) (18.1) (10.4)   
 Female 1 6 30 154 0.247  
(4.8) (7.3) (14.9) (12.1)   
Weight-for-age Z-score < −3 SDs 7 31 84 491 0.216 0.030
(16.7) (12.7) (18.7) (15.7)   
 Male 6 18 54 280 0.014  
(28.6) (11.5) (22.3) (15.4)   
 Female 1 13 30 212 0.604  
(4.8) (14.8) (14.5) (16.1)   
Mid-upper arm circumference for  
age Z-score < −3 SDs§
4 6 34 120 0.172 0.339
(15.4) (4.6) (12.8) (6.5)   
 Male 3 2 21 67 0.005  
 (21.4) (2.6) (14.6) (6.4)   
 Female 1 4 13 53 0.828  
 (8.3) (7.4) (10.7) (6.8)   
Severe acute malnutrition¶ 7 43 97 556 0.635 0.024
(16.3) (17.7) (21.8) (17.8)   
 Male 6 26 55 295 0.298  
(27.3) (16.6) (22.9) (16.3)   
 Female 1 17 42 261 0.308  
(4.8) (19.8) (20.5) (20.0)   
Height-for-age Z-score < −3 SDs 8 29 67 522 0.192 0.196
(21.1) (14.2) (18.1) (19.8)   
 Male 6 21 37 329 0.234  
(30.0) (15.7) (18.9) (21.5)   
 Female 2 8 30 193 0.427  
(11.1) (11.4) (17.1) (17.4)   
Leukocytosis 22 114 176 1273 0.004 0.057
(55.0) (49.1) (42.6) (42.9)   
 Male 9 69 96 723 0.129  
(40.9) (47.9) (43.1) (42.5)   
 Female 13 45 80 550 0.010  
(72.2) (51.1) (42.1) (43.4)   
Lymphopenia║ 14 62 138 796 0.086 0.679
(32.6) (25.1) (30.7) (25.3)   
 Male 6 42 71 453 0.425  
(27.3) (26.6) (29.3) (24.8)   
 Female 8 20 67 343 0.146  
(38.1) (22.5) (32.4) (25.9)   
C-reactive protein (mg/L), median, [IQR] 44.3 [8.1–176.4] 14.8 [3.4–44.9] 27.8 [7.2–95.7] 12.9 [3.3–39.0] <0.001 0.731
 Male 44.3 [7.8–176.4] 14.6 [4.5–39.5] 22.6 [5.2–82.9] 12.5 [3.0–37.8] <0.001  
 Female 43.5 [8.5–130.7] 15.7 [2.4–53.6] 34.4 [11.9–107.6] 13.1 [3.6–41.3] <0.001  
Underlying condition** 9 61 129 803 0.637 0.291
(20.9) (24.7) (28.7) (25.5)   
 Male 7 35 65 429 0.713  
(31.8) (22.2) (26.9) (23.5)   
 Female 2 26 64 374 0.988  
(9.5) (29.2) (30.9) (28.3)   
*Overall P value obtained from multinomial logistic regression adjusted for age and site (where applicable). P values comparing co-detection groups are presented for males and 
females together, followed by sex-stratified P values listed below the grouped P values. Bold values denote statistical significance at the P  < 0.05 level.
†Effect modification by sex, as indicated by interaction term P < 0.05 adjusted for site and age.
‡Excludes South Africa due to near uniformity of receiving oxygen at South Africa.
§Restricted to children 6 months of age or older.
¶Severe acute malnutrition: weight-for-height Z-score <-3 SD or middle arm circumference Z-score <−3 SDs or diagnosis of acute severe malnutrition.
║Below 3000 cells per microliter of blood (3 × 109/L).
**Underlying conditions: cerebral palsy, congenital heart disease/defect, congenital abnormalities, developmental delay, severe malnutrition, prematurity in an infant <6 months 
old. The number of days with cough, fever, difficulty breathing, wheeze or runny nose, whichever symptom is longest.
CoV indicates coronavirus; HDSpn, high-density streptococcus pneumoniae; IQR, interquartile range; NP/OP, nasopharyngeal/oropharyngeal; WHO, World Health Organization.
TABLE 3. (Continued).
Characteristics
No. (% with Available Information)   
A. B. C. D.
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high-density H. influenzae was not associated with mortality (CFR: 
9.5% versus 6.7%–10.5% in other groups) (Supplemental Digital 
Content 15, http://links.lww.com/INF/E363). Similarly, mortality 
was not higher relative to other groups in cases where both CoV 
and S. aureus were detected in the NP/OP, or with co-detection 
of HDSpn and influenza A/B/C, human metapneumovirus, Para 
1/3 or RSV A/B. Although influenza was rarely detected during 
PERCH, there were no deaths among the 22 HDSpn+/influenza+ 
co-detected cases. There were no differences by sex for any com-
bination of pathogens except HDSpn and Para 1/3 where co-detec-
tion had a higher CFR among females (31.3% versus 7.6%–11.1%, 
P = 0.03) but not males (8.0% versus 2.6%–9.5%, P = 0.05).
DISCUSSION
Prevalence of endemic coronavirus species detected in the 
upper respiratory tract of children <5 years hospitalized with severe 
or very severe pneumonia in pre-COVID-19 years was 7.5%, which 
was lower than prevalence in age-matched community controls 
without pneumonia (10.0%). Co-detection of human endemic CoV 
species and HDSpn, a marker of pneumococcal pneumonia, was 
infrequent (1.1%), but in male children only was associated with 
higher case fatality and more severe disease compared with detec-
tion of CoV or S. pneumoniae alone. Case fatality was 35.0% in 
co-infected males compared with 5.3%–7.1% in the other infec-
tion combinations, whereas, in females, the case fatality was 10.0% 
versus 9.2%–12.9%, respectively. High-density pneumococcus was 
detected in 12.6% of cases overall, 14.8% among those with CoV 
detected and 18.2% of cases that died with no differences by sex, 
but high-density pneumococcus was detected in 47% (n = 7) of the 
15 male children that died who had endemic CoV detected.
Endemic CoV species were not reported to be an important 
cause of severe pneumonia in the PERCH study because detection 
was low in cases and higher in controls.35 The more complex evalu-
ation of pathogen and sex interaction presented here identified a 
subset of CoV-infected children with severe disease and fatal out-
comes. Co-pathogenesis in pneumonia involves complex interac-
tions between pathogens and host. Respiratory viruses may disrupt 
the lung physiology and generate immunopathologies that promote 
subsequent bacterial infection.43 Bacterial infections can increase 
morbidity of viral infections by increasing viral load and decreas-
ing clearance.1,44 Among children with NP/OP co-detection of CoV 
and high-density pneumococcus, those that died had significantly 
higher CoV viral loads than those that survived (Supplemental 
Digital Content 9, http://links.lww.com/INF/E363). However, viral 
loads were similar between males and females among those with 
co-detection (Supplemental Digital Content 10, http://links.lww.
com/INF/E363), so high viral load alone may not explain higher 
mortality in males. Certain pathogens inhibit the host immune 
response and increase susceptibility to secondary infections.45,46 
There is evidence that CoV-NL63 strongly enhances streptococcal 
adherence to epithelial cells in human airway epithelium cultures 
and conversely does not affect adhesion of S. aureus, H. influenzae 
or Pseudomonas aeruginosa, which aligns with our findings of co-
detection with these other pathogens.33
NP/OP pneumococcal carriage itself, and not solely super-
infection in the lower respiratory tract, may play a role in sever-
ity. Virulence factors associated with nasopharyngeal colonization 
FIGURE 1. Case fatality ratio (death within 30 days of admission) among children hospitalized with severe or very severe 
pneumonia, grouped by human endemic Cov and HDSpn nasopharyngeal/oropharyngeal co-detection and stratified by sex. 
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and biofilm formation are associated with lower respiratory tract 
adhesion, development of pneumonia, invasion, inflammation and 
cytotoxicity.47 High pneumococcal nasopharyngeal density also 
primes alveolar macrophages and leads to increased responsive-
ness to pneumococcus and other pathogens.48–50 High-density 
pneumococcal carriage in the upper respiratory tract may be a 
marker of microbiome dysbiosis, and pneumococcus may play a 
role in a wider relationship between the respiratory tract microbi-
ome and severity. Studies have suggested that low-density pneu-
mococcal carriage in adults is associated with fewer microbiome 
perturbations, lower rates of viral coinfection and replication and 
decreased mucosal cytokine responses when compared with high-
density carriage or noncarriage.22 This is consistent with our find-
ings of highest mortality in children with noncarriage of pneu-
mococcus and high-density pneumococcal carriage, particularly 
with CoV detection among male children (Supplemental Digital 
Content 8, http://links.lww.com/INF/E363).22,51 The microbiome 
has sex-dependent effects on immune function and priming, and 
males have higher absolute abundance of bacteria in the upper res-
piratory tract, which could contribute to observed differences by 
sex.52,53
In most developing country settings, female children have 
lower mortality rates than males due to biological advantages, 
unless females have lower access to care or other disadvantages.54 
In the context of COVID-19 in adults, males have generally con-
stituted a higher proportion of hospitalized COVID-19 cases and 
had higher case fatality.30–32,55 IPD is also known to affect males dis-
proportionately.26–29 Behavioral and immunologic factors are likely 
to contribute some of the differential severity by sex.32,56 However, 
immunologic differences may be less pronounced in children, and 
in the PERCH study, cases were more likely to be male and case 
fatality was higher in females (8.9% versus 7.4%) suggesting pos-
sible greater care-seeking for males in this study population. This 
suggests that external biologic factors may play a role in explaining 
the excess deaths observed in male children in the PERCH study 
and our results warrant consideration of the potential role of S. 
pneumoniae in differential severity by sex.
There are important limitations to this analysis. Although 
this was a large study with almost 4000 cases and 274 deaths with 
evaluable data, the analysis required multiple stratifications that 
resulted in a small sample size of the key subgroup of interest, that 
of males and females with co-detection of CoV and high-density 
pneumococcus. As a result, we were unable to evaluate outcomes 
by endemic CoV subtypes (Supplemental Digital Content 16, 
http://links.lww.com/INF/E363). Although the investigation was 
hypothesis-driven and the PERCH study was designed to evaluate 
causes and severity of pneumonia, this was not a prespecified anal-
ysis of the main study. Therefore, results shown here could be inci-
dental and should be confirmed in other studies. There was higher 
overall mortality among female children in PERCH, suggesting 
potential conservative bias in estimates of sex differences. We used 
high-density pneumococcal detection in the NP/OP as a marker of 
pneumococcal pneumonia, but it is not a confirmatory measure as 
it has poor specificity,20 and sensitivity is reduced by prior exposure 
to antibiotics,57 which was common at PERCH sites. Furthermore, 
detection of organisms in the upper respiratory tract may not be a 
reliable surrogate for lower respiratory tract infection. Most cases 
and controls in PERCH had four or more pathogens detected on 
NP/OP, including the cases who died with CoV and high-density 
pneumococcus detected, making it difficult to attribute causation 
for any specific pneumonia case.35 One had S. aureus detected in 
pleural fluid and in PERCH was attributed at the cause of the pneu-
monia, but most of the additional organisms detected in the COV+/
high-density pneumococcus deaths were also commonly found in 
controls without pneumonia.
A further limitation was our inability to fully explore the 
effect of malnutrition on participant outcomes in this analysis. 
Results adjusted for chronic malnutrition were consistent with 
overall findings, but because of the small sample size may not have 
adequately accounted for all factors that may have contributed 
to the higher mortality in males. Although effect of sex was not 
statistically significant, males with co-detection were more likely 
to have height-for-age Z-score < −3 SDs (30.0%) compared to 
females (11.1%). Markers of severe acute malnutrition were statis-
tically different between males and females, but this may indicate 
severity of illness as vomiting, diarrhea and systemic involvement 
were more prevalent in the co-detection group and in children that 
died. Nonetheless, malnutrition associated with pediatric pneumo-
nia should be recognized as an important risk factor for mortality.58 
None of the children with co-detection who died had underlying 
conditions other than severe malnutrition. The similar prevalence of 
co-detection in community controls suggests that human endemic 
CoV species may not be a sufficient etiologic cause of pneumonia, 
alone or in combination with pneumococcus, but may interact with 
pneumococcus to exacerbate disease under specific conditions yet 
to be determined. Sensitivity analyses that increased sample size 
slightly were consistent with our primary analysis.
Any extensions from human endemic CoV species to 
COVID-19 may be inappropriate because epidemiologic and clini-
cal manifestations of SARS-CoV-2 are different from endemic 
CoV species and findings from a pediatric population may not be 
relevant to adults as children have lower severity of COVID-19 
compared with adults, possibly due to lower ACE2 receptor expres-
sion.59 Nonetheless, an analysis of adults in England’s national sur-
veillance system reported coinfection of IPD and COVID-19 being 
rare, but associated with a significant 7.8-fold increase in the case 
fatality rate.16 Carriage and IPD due to vaccine-type pneumococci 
can be reduced by pneumococcal vaccination,60 and recent reports 
have suggested a potential inverse association between pneumo-
coccal vaccination and both endemic CoV and SARS-CoV-2 infec-
tion.34,61,62 However, pneumococcal conjugate vaccine vaccination 
status was not associated with co-detection in our study.
S. pneumoniae co-pathogenesis may contribute to increased 
morbidity and mortality from CoV infection among children with 
pneumonia. Coronavirus and HDSpn co-detection was rare, but 
HDSpn was present in almost a quarter of CoV-positive very severe 
cases, and in nearly half of CoV-positive males who died. Further 
studies are needed to confirm these findings, and to elucidate the role 
of high-density pneumococcal carriage in the upper respiratory tract 
on immunologic priming, microbiome dysbiosis and other biological 
mechanisms of exacerbation. Further efforts to detect pneumococcal 
coinfection with endemic coronaviruses and SARS-CoV-2 may be 
warranted, along with potential evaluations of pneumococcal vacci-
nation and colonization density as predictors of disease progression.
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